Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07070466 · ClinicalTrials.gov registry record · Phase 2
Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA
A Phase 2 study of Stomach Cancer and Esophagus Cancer, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 2
- Study locations
NCT07070466 is a Phase 2 study of Stomach Cancer and Esophagus Cancer that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 40 participants, below the 633-participant average among 15 other Stomach Cancer trials with a reported enrollment target (94% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT07070466, a Phase 2 study of Stomach Cancer and Esophagus Cancer, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a single arm, open-label, phase II trial investigating the combination of ivonescimab with standard FOLFOX chemotherapy in 1L therapy for HER2- GEA.
Conditions Studied
Interventions
- DRUG Leucovorin
- DRUG Oxaliplatin
- DRUG Ivonescimab
- DRUG 5-Fluorouracil
Study Locations (2)
California
- UCLA - Santa Monica
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2025-10-10 |
| Est. Completion | 2028-09-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07070466
The ClinicalTrials.gov registry entry for NCT07070466 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 633-participant average among 15 other Stomach Cancer trials with a reported enrollment target (94% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Stomach Cancer appearing as the primary indexed condition, and to 4 interventions - of which Leucovorin is the first listed.
NCT07070466 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT07070466 about?
NCT07070466 is a clinical study titled "Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA". This is a single arm, open-label, phase II trial investigating the combination of ivonescimab with standard FOLFOX chemotherapy in 1L therapy for HER2- GEA.
What is the current status of trial NCT07070466?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2025-10-10. Estimated completion is 2028-09-01.
What conditions does trial NCT07070466 study?
This clinical trial studies the following conditions: Stomach Cancer, Esophagus Cancer, Stomach Cancer Stage IV.
What interventions are being tested in trial NCT07070466?
The interventions under investigation include: Leucovorin (DRUG), Oxaliplatin (DRUG), Ivonescimab (DRUG), 5-Fluorouracil (DRUG).
Who is sponsoring clinical trial NCT07070466?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07070466 being conducted?
This trial has 2 study locations across California, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stomach Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Avutometinib and Defactinib in Diffuse Gastric Cancer
RECRUITING · Phase 2
-
Perioperative mFOLFOX Plus Pembrolizumab in Gastroesophageal Junction (GEJ) and Stomach Adenocarcinoma
ACTIVE NOT RECRUITING · Phase 2
-
Adjuvant Intraperitoneal Floxuridine Added to Chemoradiation for Fully Resected Advanced Stomach Cancer
COMPLETED · Phase 2
-
Preoperative Chemo and Chemoradiotherapy for Adenocarcinoma of the Stomach and Gastroesophageal Junction (GEJ)
COMPLETED · Phase 2
-
Ph II of Capecitabine, Carboplatin & Bevacizumab for Gastroesophageal Junction & Gastric Carcinoma
COMPLETED · Phase 2
-
Brodalumab in the Treatment of Immune-Related Adverse Events
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.